Literature DB >> 2243428

Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.

J P Kane1, M J Malloy, T A Ports, N R Phillips, J C Diehl, R J Havel.   

Abstract

We conducted a randomized, controlled trial in 72 patients with heterozygous familial hypercholesterolemia to test whether reducing plasma low-density lipoprotein levels by diet and combined drug regimens can induce regression of coronary lesions. Four hundred fifty-seven lesions were measured before and after a 26-month interval by computer-based quantitative angiography. The primary outcome variable was within-patient mean change in percent area stenosis. Mean low-density lipoprotein cholesterol levels decreased from 7.32 +/- 1.5 to 4.45 +/- 1.6 mmol/L. The mean change in percent area stenosis among controls was +0.80, indicating progression, while the mean change for the treatment group was -1.53, indicating regression (P = .039 by two-tailed t test for the difference between groups). Regression among women, analyzed separately, was also significant. The change in percent area stenosis was correlated with low-density lipoprotein levels on trial. We conclude that reduction of low-density lipoprotein cholesterol levels can induce regression of atherosclerotic lesions of the coronary arteries in patients with familial hypercholesterolemia. The anticipation of benefit from treatment applies to women and men alike.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2243428

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  96 in total

Review 1.  Pathogenesis and pathology of coronary heart disease syndromes.

Authors:  P M Ridker; E M Antman
Journal:  J Thromb Thrombolysis       Date:  1999-10       Impact factor: 2.300

2.  Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association.

Authors: 
Journal:  Heart       Date:  1998-12       Impact factor: 5.994

3.  Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias.

Authors:  J G Fodor; J J Frohlich; J J Genest; P R McPherson
Journal:  CMAJ       Date:  2000-05-16       Impact factor: 8.262

4.  Hypercholesterolemia and Dyslipidemia.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-04

5.  Assessment of coronary flow reserve and microcirculation: a clinical perspective.

Authors:  Roxana Campisi; Marcelo F Di Carli
Journal:  J Nucl Cardiol       Date:  2004 Jan-Feb       Impact factor: 5.952

6.  Measuring progression and regression of coronary atherosclerosis in clinical trials: problems and progress.

Authors:  J Lespérance; D Waters
Journal:  Int J Card Imaging       Date:  1992

7.  Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke.

Authors:  S Warshafsky; D Packard; S J Marks; N Sachdeva; D M Terashita; G Kaufman; K Sang; A J Deluca; S J Peterson; W H Frishman
Journal:  J Gen Intern Med       Date:  1999-12       Impact factor: 5.128

8.  Effects of Ava II and Hinc II polymorphisms at the LDL receptor gene on serum lipid levels of Brazilian individuals with high risk for coronary heart disease.

Authors:  L A Salazar; M H Hirata; S D Giannini; N Forti; J Diament; J S Issa; R D Hirata
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

9.  Clinical and angiographic variables affecting the progression of coronary artery disease as determined by quantitative angiography.

Authors:  A Joseph; J D Talley; A Shih; T Crum; R Vogel; J Kupersmith
Journal:  Int J Card Imaging       Date:  1994-09

Review 10.  Cholesterol in patients with coronary heart disease: how low should we go?

Authors:  H B Rubins
Journal:  J Gen Intern Med       Date:  1995-08       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.